McKesson taps Brian Tyler as president, COO
McKesson has named Brian Tyler as its president and COO. Tyler will report to John Hammergren, chairman and CEO, and will become a member of the executive committee, the company announced Thursday.
“Brian is ideally suited to lead McKesson’s global operations based on his deep industry knowledge, outstanding track record as a business leader, and his commitment to operational excellence and customer success,” said Hammergren in a press statement. “His broad experience as the president of multiple McKesson businesses provides him with the ideal background and perspective to help lead McKesson’s strategic initiative and drive long-term growth.”
Tyler previously was chairman of the management board, McKesson Europe. He also served as president of McKesson North American Pharmaceutical Distribution and Services, McKesson U.S. Pharmaceutical, McKesson Medical-Surgical and McKesson Specialty Health, as well as executive vice president of corporate strategy and business development.
“McKesson has outstanding products, services and solutions, and world-class talent,” Tyler said, in the press statement. "With these assets, the company is uniquely positioned to drive innovation across the healthcare supply chain that will improve value for our business partners and enable better, more cost-effective patient care. I look forward to working with our customers, manufacturing partners and
McKesson’s more than 78,000 associates to deliver on that potential and accelerate McKesson’s growth.”
In a separate development, Nick Loporcaro, president of McKesson’s U.S. Pharmaceutical and Specialty Solutions segment, is leaving McKesson to pursue other opportunities. Tyler will lead this segment directly until Loporcaro’s replacement is named.
“Nick is a talented executive and we know he will accomplish great things in his next chapter,” said Hammergren, in a statement. “He has led McKesson Canada, McKesson Specialty Health and most recently, the combined United States Pharmaceutical and Specialty Health business. We thank him for his many contributions to McKesson and wish him the greatest success.”
“Brian is ideally suited to lead McKesson’s global operations based on his deep industry knowledge, outstanding track record as a business leader, and his commitment to operational excellence and customer success,” said Hammergren in a press statement. “His broad experience as the president of multiple McKesson businesses provides him with the ideal background and perspective to help lead McKesson’s strategic initiative and drive long-term growth.”
Tyler previously was chairman of the management board, McKesson Europe. He also served as president of McKesson North American Pharmaceutical Distribution and Services, McKesson U.S. Pharmaceutical, McKesson Medical-Surgical and McKesson Specialty Health, as well as executive vice president of corporate strategy and business development.
“McKesson has outstanding products, services and solutions, and world-class talent,” Tyler said, in the press statement. "With these assets, the company is uniquely positioned to drive innovation across the healthcare supply chain that will improve value for our business partners and enable better, more cost-effective patient care. I look forward to working with our customers, manufacturing partners and
McKesson’s more than 78,000 associates to deliver on that potential and accelerate McKesson’s growth.”
In a separate development, Nick Loporcaro, president of McKesson’s U.S. Pharmaceutical and Specialty Solutions segment, is leaving McKesson to pursue other opportunities. Tyler will lead this segment directly until Loporcaro’s replacement is named.
“Nick is a talented executive and we know he will accomplish great things in his next chapter,” said Hammergren, in a statement. “He has led McKesson Canada, McKesson Specialty Health and most recently, the combined United States Pharmaceutical and Specialty Health business. We thank him for his many contributions to McKesson and wish him the greatest success.”